OMEROS CORPORATION

OMER US6821431029

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Annual Insiders Turnover, USD ²

¹ annual and historical performance metrics are recalculated on a daily basis;
² represents the total value of insider transactions (both buying and selling);

Insider Activity

Person	Price	Shares	Total	Published	Completed
Demopulos Gregory A Md CEO	1.68 USD	15,000 Bought	25,200 USD	17/11/2023	17/11/2023
Demopulos Peter A Md	1.53 USD	10,000 Bought	15,300 USD	15/11/2023	15/11/2023

Integrated EOD Stock Data and Insider Transactions Chart

Sign in or subscribe to include OMEROS CORPORATION to your watchlist and receive automatic alerts for upcoming transactions.

Generate

The visibility of insider buy and sell transactions on this chart should not be the sole factor in your decision to buy or sell a particular stock. Always consider the following dynamic reports for a broader understanding of stock market activities:

• Insider Transaction Amount Distribution
• Insider Trading Seasonality
• Delta Correlation Analysis

 

Last	52W Low	52W High	All-Time Low	All-Time High	β

Company Insiders

Person / Entity	Transactions	Turnover, USD	Average, USD	First	Last
Demopulos Gregory A Md	1	25,200.00	25,200.00	17/11/2023	17/11/2023
Demopulos Peter A Md	1	15,300.00	15,300.00	15/11/2023	15/11/2023

Insiders marked in yellow represent long-term insiders. These are individuals who have engaged in transactions for over 3 years and have conducted at least 10 transactions or reached a cumulative turnover of $1M USD. When examining transaction clusters, we prioritize those conducted by long-term insiders for analysis.

Stock Advanced Metrics

Delta Correlation	subscribe 🔒
Upper Bound of Standardized Transaction Amount (ubsta), USD 4	subscribe 🔒

⁴ represents the maximum expected transaction amount for a company's insiders, calculated based on historical data. It provides insight into the typical range of insider transaction amounts and helps in identifying unusually large transactions.

⁵ a proprietary metric reflecting the consistency of insider trading behavior within a company. A higher discipline index suggests more regular and predictable insider transactions.